ZEVRA THERAPEUTICS INC (ZVRA)
Sector: Health Care
2026 Annual Meeting Analysis
ZVRA · Meeting: June 4, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Two Class II Directors to Hold Office Until the 2029 Annual Meeting
Calder has served since April 2023 (just over 3 years), meets the attendance threshold, is independent, brings relevant biotech industry and governance experience, and the TSR trigger does not apply — ZVRA's 3-year return of +72.1% trails the XBI (SPDR S&P Biotech ETF) by only 0.6 percentage points, well below the 65-point threshold required to trigger an against vote at this level of positive absolute return.
Watton has served since April 2023, is independent, serves on the Audit Committee with CPA credentials satisfying financial expertise requirements, met the 75% attendance threshold, and the TSR trigger does not apply for the same reason as Calder — the gap versus XBI is only 0.6 percentage points against a 65-point threshold.
Both Class II nominees are independent directors with relevant industry and financial expertise, met attendance requirements, and no policy trigger fires — ZVRA's strong 3-year absolute return of +72.1% is only 0.6 percentage points below the XBI (SPDR S&P Biotech ETF), far short of the 65-point underperformance threshold needed to trigger an against vote.
Say on Pay
✓ FORCEO
Neil F. McFarlane
Total Comp
$3,782,042
Prior Support
N/A
The CEO's total reported compensation of approximately $3.78 million is reasonable for a commercial-stage biotech CEO at ZVRA's roughly $634 million market cap, and the pay mix includes meaningful variable components — stock options, restricted stock units, and performance stock awards tied to revenue goals — alongside a 60% target bonus, keeping fixed pay well below the 40% ceiling. The company adopted performance-based equity awards (performance stock units vesting on revenue targets through 2027) in direct response to the prior year's shareholder advisory vote feedback, demonstrating responsiveness to shareholders, and a formal clawback policy compliant with Nasdaq and SEC rules is in place.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
4 yrs
Audit Fees
$973,000
Non-Audit Fees
$0
EY has served as ZVRA's auditor since June 2022 — roughly 4 years, well below the 25-year tenure threshold that would raise independence concerns — and charged zero non-audit fees in 2025, meaning 0% of fees were for non-audit work against a 50% trigger threshold, so there are no independence concerns whatsoever.
Actual Vote Results
Meeting held June 4, 2026
Director Elections
| Nominee | % FOR | Votes For | Withheld / Against | Result |
|---|---|---|---|---|
| Corey Watton | 88.6% | 29.9M | 3.8M | ✓ Elected |
| Douglas W. Calder | 76.4% | 25.8M | 8.0M | ✓ Elected |
Auditor Ratification
For 45.9M · Against 234,753 · Abstain 144,582
Other Proposals
Proposal 3
Approval of an amendment to the Company's Restated Certificate of Incorporation to phase out the classified Board structure and provide that all directors elected at or after the 2027 annual meeting of stockholders be elected on an annual basis
Overall Assessment
The 2026 ZVRA annual meeting presents a clean, uncontroversial ballot: both director nominees are independent, qualified, and face no TSR trigger (ZVRA's 3-year return nearly matches the XBI benchmark); the auditor charges zero non-audit fees and has a short tenure; and the CEO's pay program is reasonably structured with genuine performance conditions and an active clawback policy. The most notable item is Proposal 4, a board-initiated declassification of the staggered board over three years, which is a straightforward governance improvement that shareholders should support.